9. Stelara

Stelara, an IL-12,23 inhibitor, picked up $6.62 billion in sales in 2019, its 10th year on the market. (Johnson & Johnson)

Company: Johnson & Johnson
2019 sales: $6.62 billion
Projected 2026 sales: $6.32 billion
Projected CAGR: -1%
Used for: plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis

Johnson & Johnson's stalwart immunology med Stelara has long held a spot in the blockbuster rankings with its uncommon mechanism of action and a small group of approved indications. Now, Stelara has expanded its range to a fourth indiction—thanks to an FDA nod late last year—and that could help it maintain its peak sales in the years to come. 

Stelara, an IL-12,23 inhibitor, picked up $6.62 billion in sales in 2019, its 10th year on the market after an initial FDA approval in 2009. With a recent approval in ulcerative colitis, Stelara's sales are mostly expected to stay flat through 2026 at $6.32 billion, despite increasing competition and biosimilars in the field, according to Evaluate Pharma. 

That FDA nod in ulcerative colitis, granted in October, was based on two phase 3 trials showing 19% of patients on Stelara achieved remission at eight weeks, and 45% of Stelara patients hit remission by the one-year mark.

RELATED: J&J's Stelara clinches ulcerative colitis nod to back up declining Remicade

9. Stelara

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.